Exelixis (EXEL)
Exelixis Revenue Growth: -48.43%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
EXEL Revenue Growth Rankings
| Overall | 1st percentile | 4270 of 4357 |
| Sector | 5th percentile | 433 of 456 in Healthcare |
| Industry | 9th percentile | 114 of 126 in Biotechnology |
EXEL Revenue Growth Range, Past 5 Years
| Minimum | -48.43% | Mar 2012 |
| Maximum | 135.5% | Sep 2011 |
| Average | 22.48% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these EXEL related companies
EXEL News
hand-me downs found in the closet $cxz $exel $nanx.pk $rmbs any thoughts? hold or sell?
about 4 days ago by mondays
about 4 days ago by mondays
Exelixis' Management Presents at Bank of America Merrill Lynch 2012 Health Care Conference (Transcript)
May 17, 6:19PM Seeking Alpha
May 17, 6:19PM Seeking Alpha
RT @justfurkids ASCO12 "Most significant cancer drug data came from $AVEO $EXEL & phase II studies by $ARRY " http://stks.co/3rgp
about 12 days ago by russe9
about 12 days ago by russe9
ASCO12 "Most significant cancer drug data came from phase III studies by $AVEO $EXEL & phase II studies by $ARRY " http://stks.co/3rgj
about 12 days ago by justfurkids
about 12 days ago by justfurkids
$EXEL http://stks.co/3nGR Breaking out the downtrend channel will pop the price to the first target $5.81, #ASCO play
about 18 days ago by gantosj
about 18 days ago by gantosj
Exelixis Announces May 17th Webcast of Presentation at the Bank of America Merrill Lynch 2012 Health Care Conference
May 10, 4:16PM Business Wire
May 10, 4:16PM Business Wire
Exelixis' Management Presents at Deutsche Bank Securities Annual Health Care Conference (Transcript)
May 09, 8:56PM Seeking Alpha
May 09, 8:56PM Seeking Alpha
Listen to $EXEL Exelixis, Inc. at Deutsche Bank AG Health Care Conference - live at 04:50 PM, ondemand after - http://stks.co/3jNA
about 21 days ago by earningscast
about 21 days ago by earningscast
RT @peterumble Short stocks: $EXEL $RGEN $PLX $POZN $CVM , markets hate uncertainty $SPY- SPY down 3.1% POZN up 0.8% since Wed. close. DD.
about 24 days ago by Glopolon
about 24 days ago by Glopolon
$EXEL Mentioned more than normal on StockTwits - Currently at 5 x average daily social activity
about 26 days ago by TradeIdeasQuant
about 26 days ago by TradeIdeasQuant
Listen to $EXEL Q1 2012 earnings call - live at 05:00 PM, ondemand after - http://stks.co/3f7c
about 26 days ago by earningscast
about 26 days ago by earningscast
Exelixis Expands the Cabozantinib Development Program Through NCI-CTEP Collaboration
May 03, 6:50AM Benzinga
May 03, 6:50AM Benzinga
Pharmaceutical Companies Look to Biotech Industry to Combat Losses From Expiring Patents
Apr 23, 8:20AM Marketwire
Apr 23, 8:20AM Marketwire
Exelixis Announces May 3rd Webcast of First Quarter 2012 Financial Results Conference Call
Apr 19, 4:09PM Business Wire
Apr 19, 4:09PM Business Wire
Cabozantinib to be Featured in Nine Presentations at 2012 ASCO Annual Meeting
Apr 02, 6:00AM Business Wire
Apr 02, 6:00AM Business Wire
Exelixis' CEO Presents at Lazard Capital Market 8th Annual Healthcare Conference (Transcript)
Mar 13, 6:21PM Seeking Alpha
Mar 13, 6:21PM Seeking Alpha
Exelixis' CEO Presents at 30th Annual JPMorgan Healthcare Conference - Conference Call Transcript
Mar 09, 10:58AM Seeking Alpha
Mar 09, 10:58AM Seeking Alpha
Exelixis Announces March 6 Webcast of Presentation at the Cowen Health Care Conference
Mar 01, 6:00AM Business Wire
Mar 01, 6:00AM Business Wire
Exelixis' CEO Presents at Citi Global Health Care Conference (Transcript)
Feb 28, 1:13PM Seeking Alpha
Feb 28, 1:13PM Seeking Alpha
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| EXEL | 4.50 | -0.11 | -2.39% | 684.22M |
| EXE | 3.58 | +0.04 | +1.27% | 37.70M |
| EXC | 36.87 | -0.03 | -0.08% | 31.42B |
| EXBD | 38.15 | +0.26 | +0.69% | 1.262B |
| EXAS | 10.31 | +0.07 | +0.68% | 583.88M |
| EXAR | 8.00 | +0.09 | +1.14% | 355.16M |
| EXAM | 10.94 | +0.07 | +0.64% | 370.67M |
| EWZ | 53.27 | +1.13 | +2.17% | |
| EWX | 40.69 | +1.08 | +2.73% | |
| EWV | 39.25 | +0.47 | +1.21% |
